Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
Nicola A. Hanania(Baylor College of Medicine), John G. Matthews, Mark D. Eisner(Royal Victoria Infirmary), Kenneth R. Chapman, Saloumeh K Fischer(Roche (United States)), Pierluigi Paggiaro(University of Pisa), Akihito Yokoyama(Kōchi University), Cécile Holweg(Roche (United States)), Julie Olsson(Roche (United States)), Wendy S. Putnam(Roche (United States)), Charles Asare(Roche (United States)), Kun Peng(Roche (United States)), Eric D. Bateman(University of Cape Town), Sarah Gray(Roche (United States)), Petr Kopecký(Nemocnice Jindřichův Hradec), Phillip E. Korenblat
Cited by 465
Related Papers
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2010|986
Pulmonary Dead-Space Fraction as a Risk Factor for Death in the Acute Respiratory Distress Syndrome
|New England Journal of Medicine|2002|898
Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury*
|Critical Care Medicine|2005|729